All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
On 22nd August 2017, in a Letter to the Editor of the Journal of the European Academy of Dermatology and Venereology, M. Arenbergerova from Charles University, Prague, Czech Republic, et al. published a case report of male patient, 49 years of age, diagnosed in 2014 with atypical, CD23 negative, Rai stage II B-cell Chronic Lymphocytic Leukemia (CLL). Watch and wait was recommended.
In April 2015, a superficial spreading Melanoma of Breslow was excised from the left eyebrow and classified as stage IIA and with wild-type BRAF. Six months later, the patient experienced progressive left cervical lymphadenopathy and neurological symptoms (tingling of the left side of the body, loss of balance, headache). Thirteen cerebral metastases were identified by MRI and suspected to be due to melanoma progression. Stereotactic radiotherapy was not an option due to the extensive cerebral metastatic disease.
Overall, in response to pembrolizumab, the patient responded with complete response in Melanoma and stable disease in CLL. The thrombocytopenia reported may have been an adverse event of the anti-PD-1 therapy or a symptom of the CLL. The authors concluded by stating that “treatment of patients with cancer duplicities remains challenging.”
Pembrolizumab, a humanized immunoglobulin G4 monoclonal antibody against PD-1, has demonstrated antitumor activity and a manageable safety profile in patients with different solid tumors and hematologic malignancies in multiple clinical trials (1-4). Although these data highlight the effectiveness of PD-1 pathway inhibition, some patients, even those with highly immunogenic tumors, such as melanoma, do not achieve objective response (1). An increased association of B-cell chronic lymphocytic leukemia (B-CLL) and melanoma, possibly related to an underlying immunologic defect, has been previously reported (5). We still have limited data on the management of advanced stages of cancer duplicities.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox